Hualan Biological Engineering Inc
SZSE:002007
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.84
24.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Engineering Inc
Operating Income
Hualan Biological Engineering Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Hualan Biological Engineering Inc
SZSE:002007
|
Operating Income
ÂĄ1.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
12%
|
||
Beigene Ltd
HKEX:6160
|
Operating Income
-ÂĄ8.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Operating Income
ÂĄ2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
ÂĄ1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Operating Income
ÂĄ2.3B
|
CAGR 3-Years
31%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Income
ÂĄ4.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
42%
|
Hualan Biological Engineering Inc
Glance View
Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.
See Also
What is Hualan Biological Engineering Inc's Operating Income?
Operating Income
1.6B
CNY
Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Operating Income amounts to 1.6B CNY.
What is Hualan Biological Engineering Inc's Operating Income growth rate?
Operating Income CAGR 10Y
12%
Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Hualan Biological Engineering Inc have been -9% over the past three years , and 12% over the past ten years .